Abstract:Objectives: Digital therapeutics (DTx) are innovative solutions that use meaningful data to provide evidence-based decisions for the prevention, treatment, and management of diseases. Particular attention is paid to software-based in vitro diagnostics (IVDs). With this point of view, a strong connection between DTx and IVDs is observed. Methods: We investigated the current regulatory scenarios and reimbursement approaches adopted for DTx and IVDs. The initial assumption was that countries apply different regulations for the access to the market and adopt different reimbursement systems for both DTx and IVDs. The analysis was limited to the US, European countries (Germany, France, and UK), and Australia due to maturity in digital health product adoption and regulatory processes, and recent regulations related to IVDs. The final aim was to provide a general comparative overview and identify those aspects that should be better addressed to support the adoption and commercialization of DTx and IVDs. Results: Many countries regulate DTx as medical devices or software integrated with a medical device, and some have a more specific pathway than others. Australia has more specific regulations classifying software used in IVD. Some EU countries are adopting similar processes to the Digital Health Applications (DiGA) under Germany's Digitale-Versorgung Gesetz (DVG) law, which deems DTx eligible for reimbursement during the fast access pathway. France is working on a fast-track system to make DTx available to patients and reimbursable by the public system. The US retains some coverage through private insurance, federal and state programs like Medicaid and Veterans Affairs, and out-of-pocket spending. The updated Medical Devices Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) in the EU includes a classification system specifying how software integrated with medical devices, and IVDs specifically must be regulated. Conclusion: The outlook for DTx and IVDs is changing as they are becoming more technologically advanced, and some countries are adapting their device classifications depending on specific features. Our analysis showed the complexity of the issue demonstrating how fragmented are regulatory systems for DTx and IVDs. Differences emerged in terms of definitions, terminology, requested evidence, payment approaches and the overall reimbursement landscape. The complexity is expected to have a direct impact on the commercialization of and access to DTx and IVDs. In this scenario, willingness to pay of different stakeholders is a key theme.

The Revolution of Digital Therapeutics (DTx) in the Pharmaceutical Industry and Their Quality Impacts

Exploring the potential of digital therapeutics: An assessment of progress and promise

Digital Therapeutics in Perspective: From Regulatory Challenges to Post-Marketing Surveillance

Navigating the future of health care with AI-driven digital therapeutics

Digital therapeutics from bench to bedside

A comprehensive survey of the clinical trial Landscape on digital therapeutics

Clinical Evaluation of Digital Therapeutics: Present and Future

Current status and future development of digital therapeutics

Integration of personalized drug delivery systems into digital health

Preclinical and Clinical Studies Supporting Development of Drug + Digital Combination Therapies for Chronic Diseases

Revolutionizing Healthcare: A Review Unveiling the Transformative Power of Digital Twins

Tracing Digital Therapeutics Research Across Medical Specialties: Evidence from ClinicalTrials.gov

Insights into insurance coverage for digital therapeutics: A qualitative study of US payer perspectives

Exploring the Category and Use Cases on Digital Therapeutic Methodologies

The New Emerging Treatment Choice for Major Depressive Disorders: Digital Therapeutics

Access and reimbursement pathways for digital health solutions and in vitro diagnostic devices: Current scenario and challenges

Download to Heal: Navigating the Pixelated Path of Digital Therapeutics in Psychiatric Care

Digital health: trends, opportunities and challenges in medical devices, pharma and bio-technology

Characterisation of digital therapeutic clinical trials: a systematic review with natural language processing

Digital technologies: Innovations that transform the face of drug development

Toward Data-Driven Digital Therapeutics Analytics: Literature Review and Research Directions